Literature DB >> 16344717

The Arg389Gly beta1-adrenoceptor polymorphism does not affect cardiac effects of exercise after parasympathetic inhibition by atropine.

Kirsten Leineweber1, Heike Bruck, Thomas Temme, Gerd Heusch, Thomas Philipp, Otto-Erich Brodde.   

Abstract

UNLABELLED: In vitro, Arg389Gly beta1-adrenoceptor (AR) polymorphism exhibits decreased beta-AR signalling. In vivo, beta1-AR-mediated cardiac effects of exercise showed no genotype-dependent differences in Arg389 vs. Gly389 beta1-AR subjects. We studied in 16 male subjects homozygous Arg389 or Gly389 beta1-AR, whether blockade of parasympathetic activity might unmask genotype-dependence of exercise effects. Subjects were infused with atropine (10 microg/kg i.v. loading dose followed by continuous i.v. infusion of 0.15 microg/kg/min throughout exercise-time); 20 min after start of atropine bicycle-exercise in supine position (25, 50, 75 and 100 W for 5 min each) was performed and heart rate, contractility, blood pressure, plasma noradrenaline and plasma-renin activity were assessed. Exercise-evoked increases in all but one parameters were not different between Arg389 and Gly389 beta1-AR subjects; only plasma noradrenaline increased slightly more in Gly389 vs. Arg389 beta1-AR subjects. IN
CONCLUSION: It appears to be unlikely that lack of Arg389Gly beta1-AR genotype-dependence of exercise-effects can be explained by influences of parasympathetic activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16344717     DOI: 10.1097/01.fpc.0000184956.16077.93

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  5 in total

Review 1.  Mechanisms of pharmacogenomic effects of genetic variation within the cardiac adrenergic network in heart failure.

Authors:  Gerald W Dorn; Stephen B Liggett
Journal:  Mol Pharmacol       Date:  2009-06-02       Impact factor: 4.436

2.  The Arg16Gly-β(2)-adrenoceptor single nucleotide polymorphism: exercise capacity and survival in patients with end-stage heart failure.

Authors:  Kirsten Leineweber; Ulrich H Frey; Gero Tenderich; Mohammad Reza Toliat; Armin Zittermann; Peter Nürnberg; Reiner Körfer; Winfried Siffert; Gerd Heusch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-08-29       Impact factor: 3.000

3.  Functional effects of β₁-adrenoceptor polymorphisms on the hemodynamic response to dobutamine with and without β-blocker administration.

Authors:  Michael Kindermann; Ute Seeland; Patrick Ruhnke; Michael Böhm; Christoph Maack
Journal:  Clin Res Cardiol       Date:  2010-09-06       Impact factor: 5.460

Review 4.  Adrenergic receptors gene polymorphisms and autonomic nervous control of heart and vascular tone.

Authors:  L Matušková; M Javorka
Journal:  Physiol Res       Date:  2021-12-30       Impact factor: 2.139

5.  Effects of β-Adrenoceptor and Catechol-O-Methyl-Transferase (COMT) Polymorphism on Postoperative Outcome in Cardiac Surgery Patients.

Authors:  Stefan Dhein; Pascal M Dohmen; Matthias Sauer; Julia Tews; Johannes Weickmann; Anne-Kathrin Funkat; Martin Misfeld; Michael A Borger; Friedrich W Mohr
Journal:  Med Sci Monit Basic Res       Date:  2017-05-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.